Clinical Pharmacology and Therapeutics
-
Publication Venue For
-
Genetic Variants Associated With Vincristine-Induced Peripheral Neuropathy in Two Populations of Children With Acute Lymphoblastic Leukemia.
2018
-
A Pharmacogenetic Prediction Model of Progression-Free Survival in Breast Cancer using Genome-Wide Genotyping Data from CALGB 40502 (Alliance).
2018
-
Pharmacologic Targeting of Red Blood Cells to Improve Tissue Oxygenation..
104:553-563.
2018
-
Research Directions in the Clinical Implementation of Pharmacogenomics: An Overview of US Programs and Projects..
103:778-786.
2018
-
Safety and Ergogenic Properties of Combined Aminophylline and Ambrisentan in Hypoxia..
103:888-898.
2018
-
Harnessing the Power of Real-World Evidence (RWE): A Checklist to Ensure Regulatory-Grade Data Quality.
103:202-205.
2018
-
Emerging Therapies for Congestive Heart Failure..
103:77-87.
2018
-
Cancer Moonshot Data and Technology Team: Enabling a National Learning Healthcare System for Cancer to Unleash the Power of Data..
101:613-615.
2017
-
Improving the tools of clinical pharmacology: Goals for 2017 and beyond..
101:22-24.
2017
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update..
99:36-37.
2016
-
Metabolomic Signatures for Drug Response Phenotypes: Pharmacometabolomics Enables Precision Medicine..
98:71-75.
2015
-
Pharmacokinetics, Pharmacodynamics, and Safety of Lisinopril in Pediatric Kidney Transplant Patients: Implications for Starting Dose Selection..
98:25-33.
2015
-
Improving evidence developed from population-level experience with targeted agents..
97:478-487.
2015
-
Results from the IQ-CSRC prospective study support replacement of the thorough QT study by QT assessment in the early clinical phase..
97:326-335.
2015
-
GSK2374697, a Novel Albumin-Binding Domain Antibody (AlbudAb), Extends Systemic Exposure of Exendin-4: First Study in Humans—PK/PD and Safety.
96:704-712.
2014
-
Career Profile.
96:411-411.
2014
-
Phenotype standardization for statin-induced myotoxicity.
96:470-476.
2014
-
Phenotype standardization for statin-induced myotoxicity..
96:470-476.
2014
-
The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin-Induced Myopathy: 2014 Update.
96:423-428.
2014
-
The clinical pharmacogenetics implementation consortium guideline for SLCO1B1 and simvastatin-induced myopathy: 2014 update..
96:423-428.
2014
-
Use of opportunistic clinical data and a population pharmacokinetic model to support dosing of clindamycin for premature infants to adolescents..
96:429-437.
2014
-
Improving the assessment of heart toxicity for all new drugs through translational regulatory science..
95:501-508.
2014
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) Genotype and PEG Interferon-Based Regimens.
95:141-146.
2014
-
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens..
95:141-146.
2014
-
Integrated efficacy to effectiveness trials..
95:131-133.
2014
-
Pharmacometabolomics: Implications for Clinical Pharmacology and Systems Pharmacology.
95:154-167.
2014
-
Pharmacometabolomics: implications for clinical pharmacology and systems pharmacology..
95:154-167.
2014
-
Biomarkers for smoking cessation..
93:526-538.
2013
-
A Network-Heuristic Approach to Improve the Impact of Genomic Data on Drug Discovery.
93:295-297.
2013
-
Drug shortages in the United States: a critical evaluation of root causes and the need for action..
93:133-135.
2013
-
Using genetics to enable studies on the prevention of Alzheimer's disease..
93:177-185.
2013
-
Biomarkers for smoking cessation.
93:526-538.
2013
-
Integration of Pharmacometabolomic and Pharmacogenomic Approaches Reveals Novel Insights Into Antiplatelet Therapy
2013
-
Integration of pharmacometabolomic and pharmacogenomic approaches reveals novel insights into antiplatelet therapy.
94:570-573.
2013
-
Pharmacometabolomics of Statin Response
2013
-
Pharmacometabolomics of statin response.
94:562-565.
2013
-
Purine Pathway Implicated in Mechanism of Resistance to Aspirin Therapy: Pharmacometabolomics-Informed Pharmacogenomics
2013
-
Purine pathway implicated in mechanism of resistance to aspirin therapy: Pharmacometabolomics-informed pharmacogenomics.
94:525-532.
2013
-
The role of natriuretic peptides as biomarkers for guiding the management of chronic heart failure..
93:57-67.
2013
-
The clinical pharmacogenomics implementation consortium: CPIC guideline for SLCO1B1 and simvastatin-induced myopathy..
92:112-117.
2012
-
Effects of ritonavir-boosted lopinavir on the pharmacokinetics of quinine..
91:889-895.
2012
-
Impediments to clinical research in the United States..
91:535-541.
2012
-
Rational opioid dosing in the elderly: dose and dosing interval when initiating opioid therapy..
91:339-343.
2012
-
Pharmacodynamic evaluation of clopidogrel plus PA32540: the Spaced PA32540 With Clopidogrel Interaction Gauging (SPACING) study..
90:860-866.
2011
-
Paraoxonase 1 (PON1) gene variants are not associated with clopidogrel response..
90:568-574.
2011
-
The Achilles' heel of cardiovascular genetic testing: distinguishing pathogenic mutations from background genetic noise..
90:496-499.
2011
-
Practical ethics: establishing a pathway to benefit for complex pharmacogenomic tests..
90:25-27.
2011
-
Safety and pharmacokinetics of multiple-dose anidulafungin in infants and neonates..
89:702-707.
2011
-
Glycine and a glycine dehydrogenase (GLDC) SNP as citalopram/escitalopram response biomarkers in depression: pharmacometabolomics-informed pharmacogenomics..
89:97-104.
2011
-
Genetic variation in IL28B: impact on drug development for chronic hepatitis C infection..
88:708-711.
2010
-
Cough in pediatric patients receiving angiotensin-converting enzyme inhibitor therapy or angiotensin receptor blocker therapy in randomized controlled trials..
87:668-671.
2010
-
The Biomarkers Consortium: practice and pitfalls of open-source precompetitive collaboration..
87:539-542.
2010
-
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans..
87:445-451.
2010
-
Pharmacokinetics of sulfadoxine and pyrimethamine in intermittent preventive treatment of malaria in pregnancy..
87:226-234.
2010
-
Safety and pharmacokinetics of repeat-dose micafungin in young infants..
87:93-99.
2010
-
Clinical trial design in neonatal pharmacology: effect of center differences, with lessons from the Pediatric Oncology Cooperative Research experience..
86:589-591.
2009
-
Abacavir pharmacokinetics during chronic therapy in HIV-1-infected adolescents and young adults..
85:394-401.
2009
-
Erratum: Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: A meta-analysis (Clinical Pharmacology Therapeutics (2008) 84, (315-319)).
84:636.
2008
-
Racial Differences in Blood Pressure Response toAngiotensin-Converting Enzyme Inhibitors in Children: A Meta-Analysis (vol 84, pg 315, 2008).
84:636-636.
2008
-
The Reference Image Database to Evaluate Response to therapy in lung cancer (RIDER) project: a resource for the development of change-analysis software..
84:448-456.
2008
-
Corrigendum: Editorial (Clinical Pharmacology Therapeutics (2008) 84, (3-6) DOI: 10.1038/clpt.2008.99).
84:430.
2008
-
Corrigendum: Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin (Clinical Pharmacology Therapeutics (2008) 84, (326-331) DOI: 10.1038/clpt.2008.10).
84:430.
2008
-
Racial differences in blood pressure response to angiotensin-converting enzyme inhibitors in children: a meta-analysis..
84:315-319.
2008
-
Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin..
84:326-331.
2008
-
Anesthesia: a discipline that incorporates clinical pharmacology across the DDRU continuum..
84:3-6.
2008
-
Inhaled anesthesia: the original closed-loop drug administration paradigm..
84:15-18.
2008
-
Prospective study of warfarin dosage requirements based on CYP2C9 and VKORC1 genotypes..
84:83-89.
2008
-
Processed EEG (bispectral index) is not appropriate for characterizing opioid sedation..
83:667-668.
2008
-
Tamoxifen pharmacogenomics: The role of CYP2D6 as a predictor of drug response.
83:160-166.
2008
-
The importance of including swine and poultry workers in influenza vaccination programs.
82:638-641.
2007
-
The importance of including swine and poultry workers in influenza vaccination programs..
82:638-641.
2007
-
Pharmacologic advances in the global control and treatment of malaria: combination therapy and resistance..
82:601-605.
2007
-
Should the patent system for new medicines be abolished?.
82:488-490.
2007
-
Role of the centers for education and research on therapeutics (CERTs) in pharmacovigilance and proper use of therapeutics..
82:118-121.
2007
-
Population pharmacokinetics of enfuvirtide in pediatric patients with human immunodeficiency virus: searching for exposure-response relationships..
74:569-580.
2003
-
Regulating manufacturer-affiliated communication in the information age..
65:593-597.
1999
-
Stereoselective monitoring of ± verapamil treatment of women with bipolar disorder.
65:158.
1999
-
Benzodiazepine use and cognitive function among community-dwelling elderly..
64:684-692.
1998
-
Eptifibatide pharmacokinetics in patients undergoing coronary angioplasty..
63:232-232.
1998
-
Azimilide pharmacokinetics and pharmacodynamics upon multiple oral dosing.
61:205.
1997
-
Bidirectional interaction of valproate and lamotrigine in healthy subjects..
60:145-156.
1996
-
Population pharmacokinetics (PK) and pharmacodynamics (PD) of integrelin, a platelet aggregation inhibitor.
59:PI84-PI84.
1996
-
Mecamylamine combined with nicotine skin patch facilitates smoking cessation beyond nicotine patch treatment alone..
56:86-99.
1994
-
Smoking cessation, clonidine, and vulnerability to nicotine among dependent smokers..
54:670-679.
1993
-
Treatment of paroxysmal supraventricular tachycardia with oral diltiazem..
51:562-565.
1992
-
Bidisomide (SC-40230), a new antiarrhythmic agent: initial study of tolerability and pharmacokinetics..
51:371-378.
1992
-
PHARMACOKINETICS (PK) OF L-OFLOXACIN IN HIV-INFECTED PATIENTS.
51:182-182.
1992
-
Heterogeneity of CYP3A isoforms metabolizing erythromycin and cortisol..
51:18-23.
1992
-
New drug application strategies for supraventricular arrhythmias..
49:481-487.
1991
-
A COMPARISON OF PAIN, SEDATION, AND RESPIRATORY DEPRESSION FOLLOWING PENTAMORPHONE OR FENTANYL GENERAL-ANESTHESIA.
49:182-182.
1991
-
Quality of life among hypertensive patients with a diuretic background who are taking atenolol and enalapril..
48:447-454.
1990
-
Benefits, risks, and costs of prescription drugs: a scientific basis for evaluating policy options..
48:111-119.
1990
-
Transdermal nicotine facilitates smoking cessation..
47:323-330.
1990
-
NICARDIPINE VS SODIUM-NITROPRUSSIDE FOR TREATMENT OF POSTOPERATIVE HYPERTENSION.
47:198-198.
1990
-
Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients..
46:234-239.
1989
-
Dose-effect and concentration-effect relationships of pinacidil and hydrochlorothiazide in hypertension..
46:208-218.
1989
-
Erratum: Comparison between continuous and intermittent infusion regimens of cimetidine in ulcer patients (Clin Pharmacol Ther 1989; 46: 234-9).
46:500.
1989
-
Vasodilator monotherapy in the treatment of hypertension: comparative efficacy and safety of pinacidil, a potassium channel opener, and prazosin..
44:78-92.
1988
-
Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension..
43:429-435.
1988
-
Chronic effects of nitrendipine on renal hemodynamics and tubular transport..
43:6-15.
1988
-
Short-term behavioral effects of beta-adrenergic medications in men with mild hypertension.
43:429-435.
1988
-
Effects of high-dose cancer chemotherapy on the absorption of digoxin in two different formulations.
39:25-28.
1986
-
Transdermal nicotine reduces cigarette craving and nicotine preference.
38:450-456.
1985
-
Tocainide kinetics in congestive heart failure..
34:596-603.
1983
-
Hemodynamic effects of the antiarrhythmic drug pirmenol.
32:235-239.
1982
-
Effects of two nonsteroidal anti-inflammatory drugs, indomethacin and oxaprozin, on the kidney..
28:680-689.
1980
-
Nonemergency use of slow infusions of diazoxide..
18:154-157.
1975
-
Monoamine precursors in the treatment of depression..
12:743-761.
1971
-
DOSE-RELATED INFLAMMATORY EFFECTS OF INTRAVENOUS ENDOTOXIN IN HUMANS: EVALUATION OF A NEW CLINICAL LOT (CCRE LOT 94332B1) OF ESCHERICHIA COLIO: 113 ENDOTOXIN (LPS).
2018
-
PHYSIOLOGICALLY-BASED PHARMACOKINETIC MODELING OF FLUCONAZOLE USING PLASMA AND CEREBROSPINAL FLUID SAMPLES COLLECTED FROM PRETERM AND TERM INFANTS.
2018
-
INTRA-TARGET MICRODOSING (ITM), A NOVEL DRUG DEVELOPMENT APPROACH: PROOF-OF-CONCEPT IN HUMANS
2017
-
LEAN BODY WEIGHT (LBW) DOSING OF PANTOPRAZOLE IS APPROPRIATE FOR OBESE CHILDREN.
2017
-
A METFORMIN METABOLOMIC EXPRESSION PROFILE STUDY UTILIZING AN ELECTRONIC HEALTH RECORD (EHR)-LINKED BIOREPOSITORY AND INTEGRATIVE MOLECULAR EPIDEMIOLOGY APPROACHES
2016
-
ANTIFUNGAL EXTRACTION BY THE EXTRACORPOREAL MEMBRANE OXYGENATION (ECMO) CIRCUIT EX VIVO.
2015
-
VATALANIB POPULATION PHARMACOKINETICS IN PATIENTS WITH MYELODYSPLASTIC SYNDROME: CALGB 10105 (ALLIANCE)
2013
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
GLYCINE AND A GLYCINE DEHYDROGENASE (GLDC) SNP AS SSRI RESPONSE BIOMARKERS IN DEPRESSION: PHARMACOMETABOLOMICS-INFORMED PHARMACOGENOMICS
2011
-
DIFFERING SIROLIMUS-INDUCED HYPERLIPIDEMIA AND RESPONSE TO STATIN THERAPY BETWEEN CYP3A5 EXPRESSERS AND NON-EXPRESSERS IN KIDNEY TRANSPLANTATION.
2009
-
USE OF MONTE CARLO SIMULATION (MCS) TO EVALUATE TOXICITY AND EFFICACY BREAKPOINTS OF A NOVEL ANTIBIOTIC
2009